RR-11a 

RR-11a is a synthetic enzyme inhibitor of Legumain (IC₅₀=31-55 nM). RR-11a can be used for the research of cancer and acute myocardial infarction (AMI)^[1][2][3].

Legumain-targeted RR-11a-coupled nanoparticles reveal high ligand-receptor affinity, enhance solid-tumor penetration and uptake by tumor cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Treatment of tumor-bearing mice with RR-11a-coupled NPs encapsulating doxorubicin results in improved tumor selectivity and drug sensitivity, leading to complete inhibition of tumor growth^[1].
RR-11a (20 mg/kg; daily i.p. for 30 days) improves cardiac function, decreases cardiac rupture rate, and attenuates left chamber dilation and wall thinning post-AMI in mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

560.51

C₂₄H₂₈N₆O₁₀

1361390-56-8

O=C(N[C@@H](C)C(N[C@@H](C)C(NN(CC(N)=O)C(/C=C/C(ON1C(CCC1=O)=O)=O)=O)=O)=O)OCC2=CC=CC=C2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Liao D, et al. Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity. Nanomedicine. 2011 Dec;7(6):665-73.  [Content Brief]

  [2]. Ralph A, et al. Nanoparticle-based tumor-targeted drug delivery. Patent: CA2809617C

  [3]. Yang H, et al. Legumain is a predictor of all-cause mortality and potential therapeutic target in acute myocardial infarction. Cell Death Dis. 2020;11(11):1014. Published 2020 Nov 26.  [Content Brief]